Fig. 1 · Structure

Documents & Downloads

PF 4708671

Cat. No. A11755 CAS 1255517-76-0

S6 kinase inhibitor

PF 4708671 is a highly specific inhibitor of p70 ribosomal S6 kinase (S6K1) that inhibits S6K1-mediated phosphorylation of S6 protein in response to IGF-1 , while having no effect on highly related RSK and MSK kinases.

In Stock

Publications for PF 4708671

2 publications citing this product

  1. Amnon Wittenstein, .et al. , PLoS Biol, 2023, Nov 9;21(11):e3002355 PMID: 37943958
  2. Nogami A, .et al. , Transl Oncol, 2018, Nov 22;12(2):336-349 PMID: 30472492

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

PF-4708671 is used to probe S6K1 signaling. In mouse cortex it reduced S6 phosphorylation, but cellular responses require caution: AMPK/ACC phosphorylation persisted in S6K1/2-deficient fibroblasts, and isolated-mitochondria assays showed complex I inhibition (IC50 5.2 µM). [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
p70 S6K1 (Cell-free assay) 160 nM

PF 4708671 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of PF 4708671 from 3 published references. In vitro models include isolated mouse embryonic fibroblast mitochondria; APC R1450X nonsense-mutation reporter cell line.

PF 4708671 In Vitro Studies

In APC R1450X reporter cells treated with gentamicin, PF-4708671 (0.5–20 µM, 24 h) did not enhance nonsense-mutation readthrough. The quantified 20 µM comparison used four independent experiments. This negative result is specific to the tested reporter and combination. [3]

AMPK signaling persists in S6K1/2-deficient fibroblasts

Cell-based study · Wild-type and S6K1/2 double-knockout immortalized mouse embryonic fibroblasts [2]

PF-4708671 increased AMPK Thr172 and ACC Ser79 phosphorylation in both genotypes. S6 phosphorylation also decreased in knockout cells, limiting its specificity as a cellular S6K readout.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AMPK Thr172, ACC Ser79 and S6 Ser235/236 and Ser240/244 phosphorylationQualitative immunoblot response AMPK/ACC phosphorylation increased in WT and DKO; phospho-S6 decreased in DKO.[2]

Literature-Reported Treatment Conditions

Treatment concentration
3.3, 6.6 and 10 µM
Method
Immunoblotting with total AMPK/ACC and tubulin/beta-catenin controls.
Vehicle
DMSO
Co-treatment
No combination adopted.
Reported limits
Exposure duration and independent biological replicate count are not specified in the selected Fig 1 caption or shared Western blot method; duplicate lanes are not treated as independent n. S3 responses are not strictly monotonic.
Methods and source locations

Compound reported in the paper: PF-4708671; Compound label in the paper: PF-4708671

Applies to named PF-4708671 in the reported model; no salt conversion, stereochemical extrapolation or current-lot validation.

Fig 1A–B; Figs S1/S3; Methods: Cell culture and Western blot; Results, first paragraph

AMPK Thr172, ACC Ser79 and S6 Ser235/236 and Ser240/244 phosphorylation: Western blot; S3 provides densitometry without biological-n semantics. — Fig 1A–B; S1; S3

Inhibition of mitochondrial complex I

Biochemical assay · Isolated mouse embryonic fibroblast mitochondria [2]

Complex I activity decreased with PF-4708671 concentration. The assayed citrate synthase and other respiratory-enzyme comparisons did not show corresponding inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mitochondrial complex I enzymatic activityIC50 5.2 µM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Increasing concentrations in Fig 3B; 5 µM PF-4708671 in Fig 3C
Method
Rotenone-sensitive NADH–CoQ reductase assay, monitoring NADH oxidation at 340 nm; other enzyme activities measured separately.
Vehicle
DMSO
Co-treatment
Metformin (5 mM) and rotenone (1 µM) are separate comparators, not combination treatments.
Reported limits
Incubation time, independent replicate count and PF concentration for the enzyme panel in Fig 3A are not specified in its caption; no panel-wide quantitative selectivity ratio adopted.
Methods and source locations

Compound reported in the paper: PF-4708671; Compound label in the paper: PF-4708671

Applies to named PF-4708671 in the reported model; no salt conversion, stereochemical extrapolation or current-lot validation.

Fig 3A–C; Results, isolated-mitochondria paragraph; Methods: Isolation of Mitochondria and Activity of mitochondrial electron transport components

Mitochondrial complex I enzymatic activity: Reported in Results; visual trend checked in Fig 3B. This is an assay endpoint, not a cellular treatment dose. — Results, isolated-mitochondria paragraph; Fig 3B

No enhancement of gentamicin-mediated reporter readthrough

Cell-based study · APC R1450X nonsense-mutation reporter cell line [3]

Adding PF-4708671 did not enhance gentamicin-mediated nonsense suppression in this reporter model. The quantified comparison at 20 µM was reported as nonsignificant; this does not establish equivalence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GFP-BFP/GFP reporter band-intensity ratio with versus without 20 µM PF-4708671 in GM-treated cellsQualitative comparison; mean ± SD; 4 independent experiments No significant enhancement reported.[3]

Literature-Reported Treatment Conditions

Treatment concentration
0.5, 1, 5, 10 or 20 µM
Exposure duration
24 h
Method
Western blot GFP-BFP readthrough product normalized to GFP; tubulin loading control.
Vehicle
DDW for PF-4708671, as reported in Antibodies and reagents.
Co-treatment
Gentamicin (GM), 500 µg/ml; GM without PF is the relevant comparator.
Reported limits
No exact effect size or P value extracted; official slide thumbnail has limited resolution. Underlying S1 Data not acquired.
Methods and source locations

Compound reported in the paper: PF-4708671; Compound label in the paper: PF-4708671

Applies to named PF-4708671 in the reported model; no salt conversion, stereochemical extrapolation or current-lot validation.

S7 Fig and caption; Results: S6K1 negative-result paragraph; Methods: Antibodies and reagents, Western blot and Statistical analysis

GFP-BFP/GFP reporter band-intensity ratio with versus without 20 µM PF-4708671 in GM-treated cells: Western blot densitometry (Fusion-Capt); n semantics taken from S7 caption, not lane count. — S7 Fig, caption and Results S6K1 paragraph

PF 4708671 In Vivo Studies

In male CD1 mice, PF-4708671 (75 mg/kg, single intraperitoneal injection) reduced cortical S6 phosphorylation at 2 h without significantly changing FMRP S499 phosphorylation (N=6 per condition). This pharmacodynamic result does not establish efficacy or brain drug exposure. [1]

Reduced cortical S6 phosphorylation with unchanged FMRP S499

Animal study · Male CD1 mice; cortical lysates [1]

A single PF-4708671 treatment reduced cortical phospho-S6/total S6 while phospho-FMRP S499/total FMRP remained unchanged relative to vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cortical phospho-S6 Ser240/244:S6 and phospho-FMRP S499:FMRPRelative optical density; N=6 per condition; error bars SEM pS6:S6 decreased (PF versus vehicle: *P<0.05); pFMRP:FMRP not significantly changed.[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single injection
Treatment course
Cortical tissue collected 2 h after injection
Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PF-4708671 versus vehicle
75 mg/kg
DMSO vehicle; Fig 5B–C includes a separate rapamycin comparator.Reduced pS6:S6; no significant pFMRP S499:FMRP change; N=6 per condition, SEM.[1]
PF-4708671 versus vehicle
Model: Male CD1 mice; cerebral cortex
Reported limits: Exact cohort age and dosing-solution concentration not specified in selected experiment.
Methods and source locations

Compound reported in the paper: PF-4708671; Compound label in the paper: PF

Applies to named PF-4708671 in the reported model; no salt conversion, stereochemical extrapolation or current-lot validation.

Fig 5B–C; associated Results; Methods: Animals, Pharmacological Agents, Tissue Preparation, Immunoblotting and Statistical Analysis

Cortical phospho-S6 Ser240/244:S6 and phospho-FMRP S499:FMRP: Immunoblot densitometry; unpaired one-sided Mann–Whitney test as reported. Exact bar heights not transcribed. — Fig 5B–C and caption

PF-4708671 versus vehicle · Fig 5B–C and associated Results; Methods: Pharmacological Agents

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1255517-76-0
Applications S6 kinase inhibitor
Formula C19H21F3N6
Molecular Weight 390.4
SMILES
CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 30 mg/mL (76.84 mM)
Water Insoluble
Ethanol 8 mg/mL (20.49 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PF 4708671 Research References

  1. [1] Bartley CM, O'Keefe RA, Bordey A. FMRP S499 is phosphorylated independent of mTORC1-S6K1 activity PLOS ONE (2014). PMID: 24806451 DOI: 10.1371/journal.pone.0096956 Source material
  2. [2] Vainer GW, Saada A, Kania-Almog J, et al. PF-4708671 activates AMPK independently of p70S6K1 inhibition PLOS ONE (2014). PMID: 25202971 DOI: 10.1371/journal.pone.0107364 Source material
  3. [3] Wittenstein A, Caspi M, Rippin I, et al. Nonsense mutation suppression is enhanced by targeting different stages of the protein synthesis process PLOS Biology (2023). PMID: 37943958 DOI: 10.1371/journal.pbio.3002355 Source material

Publications

2 publications citing this product

  1. Amnon Wittenstein, .et al. , PLoS Biol, 2023, Nov 9;21(11):e3002355 PMID: 37943958
  2. Nogami A, .et al. , Transl Oncol, 2018, Nov 22;12(2):336-349 PMID: 30472492

Added to your cart

View Cart Checkout
Loading...